RESPOND registry

VIDEO

Type I Collagen Matrix Plus Polyhexamethylene Biguanide Antimicrobial for VLUs

06/12/2022

Dr Michael Sabolinski discusses the findings of a secondary analysis of patients with VLUs who participated in the RESPOND Registry

Dr Michael Sabolinski discusses...

06/12/2022

Wound Management & Prevention

Empirical Studies

A Prospective Noninterventional Study of Type I Collagen Matrix Plus Polyhexamethylene Biguanide Antimicrobial for the Treatment of Venous Leg Ulcers: A Secondary Analysis

06/01/2022

Michael A. Bain , MD;

George J. Koullias , MD;

Michael Leon Sabolinski , MD;

Kerry T. Thibodeaux , MD;

Analysis of VLUs in the RESPOND registry

Analysis of VLUs in the RESPOND...

06/01/2022

Wound Management & Prevention

Effectiveness of a native Type I Collagen matrix plus polyhexamethylene biguanide (PHMB) antimicrobial in the treatment of venous leg ulcers in a real-world setting

Objective: To analyze the subgroup of Venous Leg Ulcers (VLUs) in the 28 site, prospective, non-interventional, PCMP registry (RESPOND)(a) that evaluated the real-world effectiveness of P...

George J. Koullias , MD;

Michael A. Bain , MD;

Michael Leon Sabolinski , MD;

01/28/2021

Effectiveness of a native Type I Collagen matrix plus polyhexamethylene biguanide (PHMB) antimicrobial in the treatment of venous leg ulcers in a real-world setting

Objective: To analyze the subgroup of Venous Leg Ulcers (VLUs) in the 28 site, prospective, non-interventional, PCMP registry (RESPOND)(a) that evaluated the real-world effectiveness of P...

George J. Koullias , MD;

Michael Leon Sabolinski , MD;

Michael A. Bain , MD;

11/23/2020